SEC filing record
Primary Source · SEC.gov

RAPT Therapeutics, Inc.

2025 vintageSecurities Exchange Act of 1934Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form 15 / Schedule TO; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Latest signalExchange Act deregistrationForm 15-12G · 2026-03-183 events: 1 exchange act deregistration, 1 new form d filer, 1 large raiseLast filing 2026-03-18

Raised

$150M

Investors

20

Min Invest

None stated

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

RAPT Therapeutics, Inc. is an entity organized in Delaware that first filed a Form D on May 5, 2016 and most recently amended it on March 18, 2026. The offering claims Securities Exchange Act of 1934. RAPT Therapeutics, Inc. reported $149,984,200 sold from 20 investors as of the Form D filed March 18, 2026. The Form D names Leerink Partners LLC (CRD 39011), associated with None as the recipient of sales compensation soliciting in all states. The issuer's address of record is 561 Eccles Avenue, South San Francisco, CA 94080.

EDGAR Filing Data

Form 15 / Schedule TO — Primary Source

View on SEC.gov
CIK Number0001673772
Entity NameRAPT Therapeutics, Inc.
ExemptionSecurities Exchange Act of 1934
Entity Type—
Jurisdiction of OrganizationDelaware
Issuer Address561 Eccles Avenue, South San Francisco, CA 94080
Phone(650) 489-9000
Former NamesRAPT Therapeutics, Inc. (until May 15, 2026); FLX Bio, Inc. (until January 2, 2019)
Industry / Fund Type—
Securities Type—
First Sale Date—
Filing DateMarch 18, 2026
Accession Number0001193125-26-112753
Total Offering Amount$149,984,200
Total Amount Sold$149,984,200
Total Investors20
Minimum Investment$0 (no stated minimum)
Offering Duration—
State (Issuer Address)CA
Amendment Count7 filings on record

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

3

latest Mar 18, 2026

Critical / warning

0 / 1

2 watch · 0 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

5

closed, lapsed

Latest event Exchange act deregistration · Mar 18, 2026

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Investor

  • 3 filing events with values and deltas, latest 2026-03-18, and alerts on the next one
  • 5 offering timelines: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Brian Wong

Executive Officer, Director · South San Francisco, CA

Michael Giordano

Director · South San Francisco, CA

Mary Ann V. Gray

Director · South San Francisco, CA

Lori V. Lyons-Williams

Director · South San Francisco, CA

William J. Rieflin

Director · South San Francisco, CA

Linda J. Kozick

Director · South San Francisco, CA

Wendye J. Robbins

Director · South San Francisco, CA

Rodney J. Young

Executive Officer · South San Francisco, CA

Dirk J. Brockstedt

Executive Officer · South San Francisco, CA

William J. Ho

Executive Officer · South San Francisco, CA

Placement Agents and Sales Compensation (Form D)

Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.

Leerink Partners LLCCRD 39011 on BrokerCheck

Associated broker-dealer: None · Boston, MA · Soliciting in all states

Questions About RAPT Therapeutics, Inc.

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is RAPT Therapeutics, Inc.?

RAPT Therapeutics, Inc. is an issuer that filed a Form D with the SEC on March 18, 2026. The filing claims Securities Exchange Act of 1934.

Is RAPT Therapeutics, Inc. legit?

AltStreet does not rate legitimacy; it reports the public record. RAPT Therapeutics, Inc. filed a Form D with the SEC on March 18, 2026 claiming Securities Exchange Act of 1934. A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $149,984,200 sold to 20 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is RAPT Therapeutics, Inc. registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that RAPT Therapeutics, Inc. claimed Securities Exchange Act of 1934 and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has RAPT Therapeutics, Inc. raised?

RAPT Therapeutics, Inc. reported $149,984,200 sold from 20 investors as of the Form D filed March 18, 2026.

Who is selling RAPT Therapeutics, Inc. and how are they paid?

The Form D names Leerink Partners LLC (CRD 39011), associated with None as the recipient of sales compensation soliciting in all states.

Who is behind RAPT Therapeutics, Inc.?

The Form D lists 10 related persons: Brian Wong, executive officer, director; Michael Giordano, director; Mary Ann V. Gray, director; Lori V. Lyons-Williams, director; William J. Rieflin, director; Linda J. Kozick, director; Wendye J. Robbins, director; Rodney J. Young, executive officer, and 2 more. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is RAPT Therapeutics, Inc. located?

The issuer's address on its SEC filings is 561 Eccles Avenue, South San Francisco, CA 94080. Its phone number of record is (650) 489-9000. It is organized under the laws of Delaware.

How long is the RAPT Therapeutics, Inc. offering open?

An issuer must amend its Form D annually while a continuing offering stays open; 1 amendment is on record for this CIK.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.